InMed Pharmaceuticals (INM) Research & Development (2019 - 2026)

InMed Pharmaceuticals' Research & Development history runs 8 years deep, the most recent figure standing at $1.0 million for Q1 2026.

• On a quarterly basis, Research & Development rose 140.41% year-over-year to $1.0 million in Q1 2026; TTM through Mar 2026 was $2.8 million, a 6.17% increase from a year earlier, with the FY2025 full-year figure at $2.9 million, down 11.3% from the prior year.
• Research & Development improved to $1.0 million in Q1 2026 per INM's latest filing, from $630636.0 in the prior quarter.
• Across five years, Research & Development topped out at $3.6 million in Q2 2023 and bottomed at $21915.0 in Q1 2023.
• The 5-year median for Research & Development is $658869.0 (2024), against an average of $964497.1.
• Across the five-year window, Research & Development slumped 98.95% in 2022 and soared 2896.87% in 2024, its largest moves.
• Year by year, Research & Development stood at $26596.0 in 2022, then surged by 2192.79% to $609791.0 in 2023, then soared by 46.8% to $895176.0 in 2024, then fell by 29.55% to $630636.0 in 2025, then jumped by 62.16% to $1.0 million in 2026.
• Per Business Quant, the three latest INM Research & Development figures stand at $1.0 million (Q1 2026), $630636.0 (Q4 2025), and $581612.0 (Q3 2025).